RASV-Sp

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRASV-Sp

Drug Alias Namerecombinant attenuated Salmonella Typhi vaccine vectors expressing the Streptococcus pneumoniae surface protein (PspA) alpha-helical domain fused to B-lactamase (oral, Streptococcus pneumoniae infection), Arizona State UniversityRASV-Sp

ClassificationVaccines > Development/production technology > Live attenuated vaccineVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionBeta Lactamase modulators

TargetsBeta Lactamase

Therapy Area/IndicationsPneumococcal Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesArizona State University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesArizona State University

Active IndicationsN/A

Inactive IndicationsPneumococcal Infections

Other Information

ATC CodeN/A